First in China, approved clinical application of Lizhu pharmaceutical's monoclonal antibody IL-17A / F

On February 20, Lizhu pharmaceutical released the enterprise announcement Recently, Zhuhai Lizhu mAb Biotechnology Co., Ltd (hereinafter referred to as "Lizhu mAb"), a holding subsidiary of Lizhu Pharmaceutical Group Co., Ltd., and Beijing xinkanghe Biomedical Technology Co., Ltd (hereinafter referred to as "xinkanghe biology") jointly declared the "recombinant anti-human IL-17A / F humanized monoclonal antibody injection" ”The clinical trial application was approved by the State Drug Administration (hereinafter referred to as "the drug administration") "Recombinant anti-human IL-17A / F humanized monoclonal antibody injection" has been developed for 4 years, and the clinical trial application has been approved on February 19, 2020 (acceptance No.: cxsl1900130) The recombinant anti-human IL-17A / F humanized monoclonal antibody injection can simultaneously target the homologous dimer il-17a-a and il-17f-f, as well as the heterodimer il-17a-f IL-17A and IL-17F exist in the form of homologous dimer il-17a-a and il-17f-f, and heterodimer il-17a-f They are mainly produced by T helper Th17 subsets, but also by other T cells, neutrophils and mast cells These dimers, acting on receptors il-17ra and il-17rc, can promote the expression of other proinflammatory cytokines (such as IL-6, TNF α, IL-1 β, IL-20 family cytokines, GM-CSF) and effector proteins, and further lead to the activation of neutrophils and macrophages, epithelial cells and fibroblasts, which play an important role in the pathophysiology of many autoimmune diseases As of the disclosure date of the announcement, the cumulative R & D investment of "recombinant anti-human IL-17A / F humanized monoclonal antibody injection" of Lizhu pharmaceutical has been about 39.2376 million yuan In addition, according to the announcement, for IL-17A target: at present, two domestic imported products have been approved for listing in 2019, and five other domestic enterprises have been approved for clinical trials, all of which are in early clinical trials In addition, for IL-17A / F target: at present, there is no such target product in the world, and no other company in China has applied for clinical application 37